Targeting SIRT1 - a multitasker

The NAD(+)-dependent class III histone deacetylase SIRT1 modulates gene expression profiles in target tissues via regulation of transcriptional co-regulators; or by directly interacting with transcription factors. Different approaches to targeting SIRT1 can be applied therapeutically. SIRT1 activators show promise as therapies for obesity, diabetes, age-related diseases, Alzheimer's disease and stroke, while SIRT1 inhibition has been postulated for future cancer therapies and anti-HIV treatments. This article reviews the recent advances in SIRT1 research and identifies potential candidates for SIRT1-targeting therapeutics.